Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. - Wikidata - awgldk - TriplyDB

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

http://www.wikidata.org/entity/Q50764182

about

18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected Brain PET in the diagnosis of Alzheimer's disease Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function?In vivo characterization of a bigenic fluorescent mouse model of Alzheimer's disease with neurodegeneration Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography.Molecular imaging of Alzheimer disease pathology Pittsburgh compound B retention and progression of cognitive status--a meta-analysis.Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio.Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease.Abnormal Resting-State Functional Connectivity Strength in Mild Cognitive Impairment and Its Conversion to Alzheimer's Disease.Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.Alzheimer's disease diagnostic criteria: practical applications.Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients.What amyloid ligands can tell us about molecular polymorphism and disease.The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association Amyloid deposition, hypometabolism, and longitudinal cognitive decline Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort.Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.Alzheimer's disease drug development: translational neuroscience strategies.Amyloid imaging in Alzheimer's disease: a literature review.Biochemical and Radiological Markers of Alzheimer's Disease Progression.Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI.Radiopharmaceuticals for Assessment of Altered Metabolism and Biometal Fluxes in Brain Aging and Alzheimer's Disease with Positron Emission Tomography.Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease.A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment.Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD).

P2860

Q24186399-6FB52900-8CAC-462E-835C-2D750BC3F90C Q24194742-32C05068-19EA-4383-A3AF-FFD7A2EC1141 Q27007436-0733F23F-B391-42F9-9A72-BF71740A4B3A Q27011549-3B009421-CE75-4A6D-B5DF-5923FBD3964C Q30666527-64117C17-E8A6-41C3-B1CB-6441D55C5B99 Q31096423-DC6CC7AB-95C8-45B3-8205-AA8C79043448 Q33624586-CEA28D08-3F65-47DE-B922-5E4C7036D4DE Q33695122-799A7A58-FB20-41C5-A05C-6A1292CC085C Q33726628-A14E49A3-F8DD-4873-85C9-0F1D58D5A5F4 Q33872248-6EC81052-2160-44A0-8BAD-63BADE53C5BA Q34050850-1D904BE7-4A9E-44DB-9917-1EE5BB4A0EB2 Q34378321-53BF6C6B-5663-46F5-B5B7-CF5A67028A8C Q34651135-55B31145-A4D1-4CA0-BF24-A0D49533307B Q35115487-349333BD-4E7B-46C2-9181-EE66C103EE1B Q35735066-B91D8E2E-8C75-4AAD-A4D5-0FEEC20457A6 Q36034391-6DA42081-D2F0-4730-8735-4131212ECE87 Q36217479-03A76746-8E65-4796-B2AF-4648AB860EC1 Q36267484-6A38A67A-E026-40CE-97F7-7EBE7251A12D Q36408912-A75B7F43-10D5-42CE-9D69-94BE0CCA906C Q36457301-83F3FEE8-935C-4B79-B348-F6EFCD75B0D5 Q36515507-7771974D-6E9C-4613-93EE-09B1159E9A42 Q36632807-0D2CE7D5-2056-4C00-A56A-8E0CA3E9200C Q36662808-DAF88E4B-B338-479D-9012-443901D858E3 Q36871202-DF4B00BC-3061-43BD-B3BB-581830AD11FD Q37029599-E37FAAD8-2727-43EE-87F1-514C78C22B1C Q37069527-CBB8F35E-0357-4862-BE4F-4FC1AA13E23A Q37207254-F145FCBA-9488-4237-B7FE-6D0787A20356 Q37485059-0A1198BB-B778-4614-A672-9686F6ECBAC2 Q37603879-B5B99D3E-E4A3-4EE2-93E4-F70F9F61DFAD Q38087640-C0E58282-7929-4822-B65F-5468EDB14F0A Q38250091-D2E6139E-B42C-40C8-9EF1-1B2D409BECB2 Q38693438-9F31822B-5614-4BC6-B95A-6253C17463C6 Q39343733-FEC87691-C96A-42B4-90CF-F00EFBF816BB Q41535994-9FF5C115-C4A8-44DD-A089-E2977BDE096E Q42656272-2AEFCE56-60EB-4839-8557-9AB6959467AF Q48132965-2C093C45-D286-4FBF-A46A-A4F9487A539B Q48162688-7A3EC410-031F-4E82-B0C8-B26E89281F89 Q50239485-06838BF6-37B7-487E-A3C8-42E612051501 Q50563459-AD6C14A6-E904-4E11-9E90-8588EBF34580 Q52609373-297415C4-4280-4DD2-BDF2-ECEC0D3297CC

P2860

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

http://www.wikidata.org/entity/Q50764182

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

@en

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

@nl

type

label

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

@en

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

@nl

prefLabel

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

@en

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

@nl

P1433

Q50764182-823B7CB4-7452-44A9-9580-946C4CDA02F6

P1476

Q50764182-39A96DFE-CFDD-4147-ABF2-06FD0BEC7FC6

P2093

Q50764182-0279E773-5C21-431C-9201-A96AC2039526

Q50764182-25D5208C-F76C-4223-B003-6CE67F306803

Q50764182-4B59A88D-303F-4612-8DA4-B4511FDD494A

Q50764182-7DBA157F-BEB1-4F44-A2A4-08F1F0020BE9

Q50764182-A726C6FC-0B2A-4A88-B1BD-367B3B1036C6

P2860

Q50764182-04FBA7ED-8456-441A-BCAD-15BF092114CB

Q50764182-067FD4D4-B224-4E8C-BAA9-674635C0D6F4

Q50764182-073AB6F7-399F-445F-AD30-11E4796CA987

Q50764182-07D4A9E5-F6AF-4363-91E5-29C245135CCD

Q50764182-0A15CB17-5575-4A6E-9F3D-3B72007074F4

Q50764182-0A9CC07C-578C-4AD2-902C-B5ACB0DAE2EB

Q50764182-0CB1A769-6CB5-4A5F-A6D1-916A473D7DE5

Q50764182-316FC251-1359-467C-A9F8-883E49E57271

Q50764182-32814EBC-B739-46FA-83FE-6B4B552BFD32

Q50764182-3C966EA2-3FB5-4C87-8302-D33892BA5D93

P2888

Q50764182-2F796095-C00E-4BB5-A9FA-5E125316FC6F

P304

Q50764182-C39D6E8A-25F9-4473-B8D8-30A02C5FF4F8

P31

Q50764182-FC450233-A52B-412E-98CE-52B8972AD300

P356

Q50764182-1C1C19A8-5258-46A0-AE20-D8034D26905F

P433

Q50764182-FEADF0C8-D065-4261-94B2-8E816F4AB182

P478

Q50764182-C5B56155-AE4F-4314-99AC-582301B093D0

P50

Q50764182-238623E3-F855-4257-A00A-02B1A5D108C1

Q50764182-5C7F7221-023D-495A-A752-411F163F0A55

Q50764182-86E7AC70-2972-42ED-A844-33FA20848BF8

Q50764182-A16D30C9-16B9-4F4D-A05D-CA46ED83B049

Q50764182-AD23097B-B164-470C-925D-C3672BABFFC7

Q50764182-E5F9AA14-D9A7-403E-AAF6-7519671BE515

Q50764182-F07276BC-544B-4077-B28F-697744ACF8BD

P577

Q50764182-388E09C6-BA9A-43E3-85D7-3642C7BFE1D5

P698

Q50764182-BEFCAC2C-9125-4E00-8E47-E35525237065

P921

Q50764182-6abf0724-b926-4476-aa27-2ee062a48192

P356

S00259-012-2102-3

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

@en

P2093

Bart N M van Berckel

http://www.w3.org/2001/XMLSchema#string

Jessica C Foster-Dingley

http://www.w3.org/2001/XMLSchema#string

Maqsood Yaqub

http://www.w3.org/2001/XMLSchema#string

Nelleke Tolboom

http://www.w3.org/2001/XMLSchema#string

Sofie F Adriaanse

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Mild cognitive impairment: clinical characterization and outcome

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies.

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

P2888

s00259-012-2102-3

P304

990-1000

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-012-2102-3

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Philip Scheltens

Albert D. Windhorst

Ronald Boellaard

Frederik Barkhof

Adriaan A Lammertsma

Wiesje van der Flier

Rik Ossenkoppele

P577

2012-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22441582

http://www.w3.org/2001/XMLSchema#string

P921